Antagonists of leukotriene D4 (LTD4), 3-[7-(2-n-propyl-3-hydroxy-4-acetyl- phenoxy)-propoxy-2-methyl-3,4-dihydro-4-8-n-propyl-2H-1-benzopyran- 2-yl]-propionic acid (SC-39070) and 7-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-2-hydroxy- propoxy]-4-methyl- 2-oxo-2H-1-benzopyran-3-acetic acid (FPL-60319) were locally administered to eyes of rabbits with immunogenic keratitis. The period of circular leukocyte infiltration (Wessely's ring) in the cornea was markedly decreased. Edema and neovascularization of the cornea were not influenced.

Download full-text PDF

Source
http://dx.doi.org/10.1159/000267130DOI Listing

Publication Analysis

Top Keywords

immunogenic keratitis
8
topical administration
4
administration leukotriene
4
leukotriene antagonists
4
antagonists immunogenic
4
keratitis antagonists
4
antagonists leukotriene
4
leukotriene ltd4
4
ltd4 3-[7-2-n-propyl-3-hydroxy-4-acetyl-
4
3-[7-2-n-propyl-3-hydroxy-4-acetyl- phenoxy-propoxy-2-methyl-34-dihydro-4-8-n-propyl-2h-1-benzopyran-
4

Similar Publications

BACKGROUND Trastuzumab (Herceptin) is a recombinant DNA-derived humanized monoclonal antibody that the US Food and Drug Administration (FDA) approved in 1998 for metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer therapy. It selectively binds to the extracellular domain of HER2 and mediates an antibody-dependent cellular toxicity in various tissues. Trastuzumab use alone does not typically cause aggressive ocular complications.

View Article and Find Full Text PDF
Article Synopsis
  • Primary atopic disorders (PAD) are rare genetic conditions caused by specific gene variants that affect skin and immune function, making diagnosis challenging among common allergic disease cases.
  • Identifying PAD requires recognizing clinical red flags like family history and unusual infections, as conventional lab tests are inadequate for definitive diagnosis.
  • Whole-genome sequencing (WGS) enhances diagnostic efficiency and accuracy, but requires careful interpretation and collaboration among specialists to effectively manage PAD cases.
View Article and Find Full Text PDF

Presence of CD80 and Absence of LAT in Modulating Cellular Infiltration and HSV-1 Latency.

Viruses

August 2024

Center for Neurobiology and Vaccine Development, Ophthalmology Research, Department of Surgery, Cedars-Sinai Burns & Allen Research Institute, CSMC - SSB3, 8700 Beverly Blvd., Los Angeles, CA 90048, USA.

CD80 is the best-known costimulatory molecule for effective T cell functions. Many different reports have summarized the role of CD80 in HSV-1 and its functions in maintaining adaptive immunity, which is the main player in causing herpes stromal keratitis (HSK). To determine the effects of absence or overexpression of CD80 in HSV-1 infection, we infected CD80 and WT mice with a recombinant HSV-1 expressing murine CD80 (HSV-CD80) in place of the latency associated transcript (LAT).

View Article and Find Full Text PDF
Article Synopsis
  • * This study tested sodium butyrate (NaB), which can reduce pro-inflammatory cytokines and promote anti-inflammatory ones, to see if it could improve keratitis treatment.
  • * Results showed that NaB did not harm corneal fibroblast viability, helped maintain a healthy cell type, inhibited cell movement, and reduced inflammation by targeting the JAK/STAT signaling pathway.
View Article and Find Full Text PDF

Dual Role of : Commensal Bacterium and Pathogen in Ocular Diseases.

Microorganisms

August 2024

Department of Frontier Medical Science and Technology for Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan.

Article Synopsis
  • * A specific bacteria, which is common in the eye, decreases in abundance as we age and can behave as both an infectious agent and an immune trigger.
  • * The review focuses on how this bacteria contributes to various eye inflammations, affecting diagnosis and treatment strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!